SIGA SIGA TECHNOLOGIES INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1010086 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-69.6%
TTM net income YoY-99.1%
TTM EPS YoY-99.0%
Revenue 3-yr CAGR14.6%
Net income 3-yr CAGR—
Margins
Gross margin54.0%
Operating margin-14.2%
Net margin1.3%
FCF margin-22.1%
EBITDA margin-13.0%
Returns
ROE0.4%
ROA0.3%
ROIC (approx.)-15.0%
Asset turnover0.26x
Leverage & solvency
Liabilities / assets5.4%
Debt / equity0.00x
Current ratio24.57x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-16.81x
Accruals ratio6.0%
Payout ratio6,325.2%
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.32M | $41.00M | $6.24M | $3.79M | $2.62M | $81.12M | $7.04M | $81.47M |
| Cost of revenue | $575,660 | $17.56M | $2.94M | $2.99M | $1.00M | $25.55M | $157,738 | $14.13M |
| Gross profit | $741,305 | $23.44M | $3.30M | $804,474 | $1.62M | $55.57M | $6.88M | $67.34M |
| R&D expense | $2.64M | $4.39M | $3.95M | $5.04M | $7.05M | $4.40M | $3.46M | $3.34M |
| SG&A expense | $4.62M | $5.15M | $4.67M | $5.26M | $4.79M | $5.49M | $5.68M | $6.91M |
| Operating income | -$6.52M | $13.91M | -$5.32M | -$9.50M | -$10.22M | $45.68M | -$2.26M | $57.09M |
| Pretax income | -$5.48M | $14.85M | -$4.04M | -$7.96M | -$8.36M | $47.27M | -$570,415 | $58.58M |
| Income tax | -$2.59M | $2.39M | -$589,432 | -$2.53M | -$1.99M | $11.79M | -$162,192 | $12.82M |
| Net income | -$2.89M | $12.46M | -$3.45M | -$5.43M | -$6.37M | $35.48M | -$408,223 | $45.76M |
| EBITDA | -$6.37M | $14.06M | -$5.17M | -$9.35M | -$10.08M | $45.82M | -$2.12M | $57.22M |
| EPS (basic) | -0.04 | 0.17 | -0.05 | — | -0.09 | 0.50 | -0.01 | — |
| EPS (diluted) | -0.04 | 0.17 | -0.05 | — | -0.09 | 0.49 | -0.01 | — |
| Dividends declared per share | 0.60 | 0.60 | 0.60 | 0.00 | 0.00 | 0.60 | — | 0.00 |
| Weighted avg. shares (diluted) | 71.85M | 71.88M | 71.65M | — | 71.60M | 71.75M | 71.43M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $116.38M | $117.58M | $145.56M | $154.97M | $171.96M | $182.46M | $162.27M | $155.40M |
| Receivables | $2.02M | $7.17M | $4.50M | $3.26M | $2.49M | $6.49M | $7.19M | $21.17M |
| Inventory | $41.59M | $41.11M | $56.49M | $49.05M | $48.01M | $35.62M | $59.06M | $49.56M |
| Current assets | $165.54M | $170.38M | $211.53M | $212.86M | $227.75M | $229.20M | $233.62M | $231.04M |
| PP&E, net | $1.38M | $1.53M | $1.67M | $1.09M | $1.20M | $1.05M | $1.19M | $1.30M |
| Goodwill | $898,334 | $898,334 | $898,334 | $898,334 | $898,334 | $898,334 | $898,334 | $898,334 |
| Total assets | $172.65M | $175.74M | $219.39M | $219.47M | $231.60M | $235.33M | $247.07M | $244.34M |
| Current liabilities | $6.74M | $7.85M | $65.16M | $17.99M | $24.84M | $22.72M | $27.80M | $25.33M |
| Total liabilities | $9.39M | $10.45M | $67.77M | $20.65M | $28.12M | $26.02M | $30.93M | $28.53M |
| Shareholders' equity | $163.25M | $165.29M | $151.62M | $198.82M | $203.48M | $209.31M | $216.13M | $215.80M |
| Shares outstanding | 71.86M | 71.84M | 71.72M | 71.61M | 71.61M | 71.54M | 71.44M | 71.40M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.18M | $15.17M | -$8.66M | -$16.86M | -$9.81M | $63.08M | $7.06M | $56.31M |
| Capital expenditure | $0 | $0 | $0 | $40,539 | $289,576 | $1 | $24,893 | $17,838 |
| Free cash flow | -$1.18M | $15.17M | -$8.66M | -$16.90M | -$10.10M | $63.08M | $7.04M | $56.29M |
| Investing cash flow | $0 | $0 | $0 | -$40,539 | -$289,576 | -$1 | -$24,893 | -$17,838 |
| Financing cash flow | -$22,480 | -$43.15M | -$740,377 | -$87,823 | -$403,480 | -$42.89M | -$166,193 | -$161,756 |
| Depreciation & amortization | $154,793 | $152,219 | $149,949 | $146,518 | $141,795 | $138,986 | $135,308 | $130,729 |
| Stock-based compensation | $860,302 | $1.21M | $752,965 | $772,540 | $774,104 | $1.23M | $902,280 | $764,070 |
| Dividends paid | $9,000 | $43.15M | $159,380 | $87,823 | $162,023 | $42.87M | $0 | $0 |
| Share buybacks | — | — | — | — | — | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.